Eidos Therapeutics

0 followers

‌

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanfor... Read more

Industries

Headquarters

San Francisco, United States

Employees

Links

Org chart

Chief Executive Officer

Neil Kumar

Collapse

Chief Scientific Officer

Chief Commercial Officer

Senior Vice President, Corporate Development

Vice President, Quality and Compliance

Senior Vice President, Clinical Development

Stuart Heminway

Senior Vice President, Regulatory Affairs, BridgeBio Cardiorenal

Suresh Siddhanti

Vice President, Clinical Development

Teams

Clinical Research and Development

6 members

Leadership Team

5 members

Research and Development

4 members

Quality Assurance and Compliance

3 members

Offices

Similar companies

Summit Therapeutics

4 followers

Pivot Bio

2 followers

Generation Bio

2 followers

ALS Therapy Development Institute

3 followers

Genesis Therapeutics

3 followers

Gilead Sciences

135 followers

Verily Life Sciences

38 followers

BioMarin Pharmaceutical

36 followers

Sarepta Therapeutics

9 followers

PerkinElmer

9 followers

United Therapeutics

8 followers

Explore companies